BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17374814)

  • 1. One-year cardiovascular event rates in outpatients with atherothrombosis.
    Steg PG; Bhatt DL; Wilson PW; D'Agostino R; Ohman EM; Röther J; Liau CS; Hirsch AT; Mas JL; Ikeda Y; Pencina MJ; Goto S;
    JAMA; 2007 Mar; 297(11):1197-206. PubMed ID: 17374814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular complications at 1-year of follow-up in patients with atherothrombosis. On behalf of Spain's REACH Registry].
    Suárez C; Castillo J; Esmatjes E; Sala J; Cairols M; Montoto C; Barberá G;
    Med Clin (Barc); 2009 Apr; 132(14):537-44. PubMed ID: 19393390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.
    Bhatt DL; Eagle KA; Ohman EM; Hirsch AT; Goto S; Mahoney EM; Wilson PW; Alberts MJ; D'Agostino R; Liau CS; Mas JL; Röther J; Smith SC; Salette G; Contant CF; Massaro JM; Steg PG;
    JAMA; 2010 Sep; 304(12):1350-7. PubMed ID: 20805624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
    Baumgartner I; Hirsch AT; Abola MT; Cacoub PP; Poldermans D; Steg PG; Creager MA; Bhatt DL;
    J Vasc Surg; 2008 Oct; 48(4):808-14. PubMed ID: 18639426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.
    Alberts MJ; Bhatt DL; Mas JL; Ohman EM; Hirsch AT; Röther J; Salette G; Goto S; Smith SC; Liau CS; Wilson PW; Steg PG;
    Eur Heart J; 2009 Oct; 30(19):2318-26. PubMed ID: 19720633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis.
    Reid CM; Ademi Z; Nelson MR; Connor G; Chew DP; Shiel L; Smeath A; De Looze F; Steg PG; Bhatt DL; Liew D;
    Med J Aust; 2012 Feb; 196(3):193-7. PubMed ID: 22339526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
    Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year.
    Sabouret P; Cacoub P; Dallongeville J; Krempf M; Mas JL; Pinel JF; Priollet P; Steg G; Taminau D; Montalescot G;
    Arch Cardiovasc Dis; 2008 Feb; 101(2):81-8. PubMed ID: 18398391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
    Cacoub PP; Abola MT; Baumgartner I; Bhatt DL; Creager MA; Liau CS; Goto S; Röther J; Steg PG; Hirsch AT;
    Atherosclerosis; 2009 Jun; 204(2):e86-92. PubMed ID: 19054514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
    Uchiyama S; Goto S; Matsumoto M; Nagai R; Origasa H; Yamazaki T; Shigematsu H; Shimada K; Yamada N; Bhatt DL; Steg PG; Ikeda Y;
    J Neurol Sci; 2009 Dec; 287(1-2):45-51. PubMed ID: 19815240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
    Goto S; Bhatt DL; Röther J; Alberts M; Hill MD; Ikeda Y; Uchiyama S; D'Agostino R; Ohman EM; Liau CS; Hirsch AT; Mas JL; Wilson PW; Corbalán R; Aichner F; Steg PG;
    Am Heart J; 2008 Nov; 156(5):855-63, 863.e2. PubMed ID: 19061698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
    Darmon A; Elbez Y; Bhatt DL; Abtan J; Mas JL; Cacoub P; Montalescot G; Billaut-Laden I; Ducrocq G; Steg PG
    Ann Cardiol Angeiol (Paris); 2020 Oct; 69(4):158-166. PubMed ID: 32778388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
    Krempf M; Parhofer KG; Steg PG; Bhatt DL; Ohman EM; Röther J; Goto S; Pasquet B; Wilson PW;
    Am J Cardiol; 2010 Mar; 105(5):667-71. PubMed ID: 20185014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
    Bhatt DL; Steg PG; Ohman EM; Hirsch AT; Ikeda Y; Mas JL; Goto S; Liau CS; Richard AJ; Röther J; Wilson PW;
    JAMA; 2006 Jan; 295(2):180-9. PubMed ID: 16403930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.
    Kohli P; Steg PG; Cannon CP; Smith SC; Eagle KA; Ohman EM; Alberts MJ; Hoffman E; Guo J; Simon T; Sorbets E; Goto S; Bhatt DL;
    Am J Med; 2014 Jan; 127(1):53-60.e1. PubMed ID: 24280110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH Registry.
    Gaxiola E; Eng-Ceceña L; Ortiz-Galván F; Llamas-López L; Rangel-Guerra R; Alcocer-Gamba MA; Bhatt DL; Gabriel Steg P;
    Clin Cardiol; 2010 Jul; 33(7):445-51. PubMed ID: 20641123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry.
    Venketasubramanian N; Röther J; Bhatt DL; Pasquet B; Mas JL; Alberts MJ; Hill MD; Aichner F; Steg PG;
    Cerebrovasc Dis; 2011; 32(3):254-60. PubMed ID: 21876353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
    Bangalore S; Steg G; Deedwania P; Crowley K; Eagle KA; Goto S; Ohman EM; Cannon CP; Smith SC; Zeymer U; Hoffman EB; Messerli FH; Bhatt DL;
    JAMA; 2012 Oct; 308(13):1340-9. PubMed ID: 23032550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry.
    Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Steg PG; Cannon CP; Brennan DM; Bhatt DL;
    Crit Pathw Cardiol; 2009 Jun; 8(2):91-7. PubMed ID: 19417637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry.
    Ducrocq G; Bhatt DL; Labreuche J; Corbalan R; Porath A; Gao R; Panchenko E; Liau CS; Ikeda Y; Goto S; Amarenco P; Steg PG
    Eur J Prev Cardiol; 2014 Dec; 21(12):1509-16. PubMed ID: 23965467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.